

Primary Progressive Multiple Sclerosis Treatment Market to Surpass USD 3.2 Billion by 2031 | TMR Study

Growth in prevalence of primary progressive multiple sclerosis is significantly impacting market development

WILMINGTON, DELAWARE, UNITED STATES, October 25, 2023 /EINPresswire.com/ -- [Primary Progressive Multiple Sclerosis Treatment Market](#) is expected to witness significant growth in the coming years, according to a new report. The market was valued at USD 828.4 million in 2021 and is projected to reach over USD 3.2 billion by 2031, expanding at a compound annual growth rate of 14.7% during the forecast period.

For more information, contact Transparency Market Research at https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85270



Transparency Market Research is a leading global provider of market research reports and consulting services.

The rising geriatric population globally is a major factor fueling the demand for primary progressive multiple sclerosis treatment. As age is a high-risk factor, the increasing elderly demographic will support market expansion over the forecast period.

Transparency Market Research is a leading global provider of market research reports and consulting services.

Rise in prevalence of PPMS across the globe due to the growing geriatric population is a key

factor fueling demand. Women are more susceptible to multiple sclerosis than men. With more people being diagnosed with the disease, treatment needs are increasing. Effectiveness of available drugs and ongoing research for new therapies are further supporting market growth.

Key Market Drivers:

Growing prevalence of multiple sclerosis worldwide

Increasing research and development activities for novel treatment options

Rising healthcare expenditure in many countries

Key Market Challenges:

High cost of treatment and lack of reimbursement in some regions

Absence of approved disease-modifying therapies for primary progressive MS

Long development timelines and high failure rates of drug candidates

Key Market Opportunities:

Shift from generic drugs to specialty medicines

Focus on development of oral and more efficacious drugs

Emergence of biologics and monoclonal antibodies

Key Market Segments:

https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=85270

Key Market Segments:

Key Market Segments:

Approved Drugs

Pipeline Drugs

Key Market Segments:

Retail Pharmacies

E-commerce

Others

□□□□□□□□ □□□□□□ □□ □□ □□□□□□ □□□□□□

Hoffmann-La Roche Ltd.

Sanofi

Mapi Pharma Ltd.

Atara Biotherapeutics

Takeda Pharmaceuticals International, Inc.

AB Science

Mallinckrodt

□□□□ □□□ □□□□□? □□□ □□□ □□□□□□□□

https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=85270

□□□□ □□□□□□□□□□ □□□□□□□□ □□ □□□□ □□□□□□□:

How big was the global primary progressive multiple sclerosis treatment market in 2021?

How much worth would the industry be in 2031?

What will be the CAGR during the forecast period?

What was the CAGR during the period of 2017 to 2021?

Which region is expected to hold major share during the forecast period?

Who are the prominent players in the global primary progressive multiple sclerosis treatment market?

□□□□□□ □□□□ □□□□□□□□□□ □□□□□□□□ □□ □□□□□□□□□□□□ □□□□□□ □□□□□□□□□-

[Benign Prostatic Hyperplasia Treatment Market](#)

Increasing adoption of minimally invasive surgeries is fueling benign prostatic hyperplasia

treatment market expansion. Rising male elderly population is expected to drive market growth.

[Psoriatic Arthritis Therapeutics Market](#)

Technological advancements in drug delivery system, is another factor that is anticipated to stimulate the psoriatic arthritis therapeutics market share in the coming years. Increasing research & development activities is a major factor that is anticipated to escalate the market growth

Nikhil Sawlani

Transparency Market Research Inc.

+ +1 518-618-1030

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/664131848>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.